Mizuho Maintains Bearish View on Relypsa (RLYP) Despite Q1 Top-Line Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Relypsa Reports First Quarter 2016 Financial Results
May 4, 2016 4:08 PM EDTRelypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT
REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ: RLYP), a biopharmaceutical company, today reported financial results for the quarter ended March 31, 2016. Total revenues for the first quarter 2016 were $12.4 million, which included net product revenues of $0.6 million from Veltassa® (patiromer) for oral suspension and collaboration and license revenue of $11.8 million.
We made great progress in our first full quarter with Veltassa on the market. We saw solid month-over-month growth of prescriptions, reported early success... More
